The compounding pharmacies in the US is currently at a nascent stage of business expansion, with handful of pharmaceuticals companies partaking in its growth. The expansion of US compounding pharmacies market size, however, is not likely to be as nascent since the top participants in the market are contributing tremendous effort towards proliferation. Compounded drugs, unlike other drug types, have restricted therapeutic use and need detailed prescription and observation for prolonged use. Future Market Insights (FMI) has recorded the profiles and determinations of key players in the US compounding pharmacies market, which are surging upward by dodging such limitations.
Among the leading companies influencing the growth of the US compounding pharmacies market value include PharMEDium Services LLC and Cantrell Drug Company. PharMEDium Services, a part of AmerisourceBergen, has impacted the growth of compounding pharmacies market in the US by strategic tie-ups with prominent pharmacy service providers. One of the recent instance of a profitable collaboration by the company was when it renewed its sole source agreement with Premier, Inc., a sought-after pharmacy service provider in US. The agreement comprised of a vast range of compounded drugs and medicinal services for pain management, nerve block, labour, and operating room anaesthesia, among others. On the other hand, Cantrell Drug Company boosted its presence on the US compounding pharmacies market value by enhancing existing product portfolio. The company recently reported its enhancement in compounding safety by implementing Closed Vial Filling (CVF) system from the use of sterile technologies.
Other leading participants in the US compounding pharmacies market include, Institutional Pharmacy Solutions and Triangle Compounding Pharmacies. To know more on how these companies stimulated the growth of the US compounding pharmacies market value, request a free sample of FMI’s report at www.futuremarketinsights.com/reports/sample/rep-us-978.
